Stock comparison
Mettler-Toledo International
PTC Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
PTCT
PTC Therapeutics
Market cap
$5.71B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | PTCT | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 57D | MTD |
| Benjamin Graham | 65B | 35D | MTD |
| Philip Fisher | 63C | 63C | Tie |
| Peter Lynch | 66B | 62C | MTD |
| Joel Greenblatt | 68B | 4F | MTD |
| Charlie Munger | 74B | 55D | MTD |
| Terry Smith | 70B | 57C | MTD |
Side-by-side metrics
| Metric | MTD | PTCT |
|---|---|---|
| Market cap | $22.29B | $5.71B |
| P/E (TTM) | 25.3x | - |
| EV/EBIT | 21.6x | 6.2x |
| ROIC (TTM) | 36.09% | -2.38% |
| Gross margin | 57.79% | 77.84% |
| Net margin | 21.4% | -22.58% |
| Revenue CAGR 5y | 2.01% | 33.89% |
| EPS CAGR 5y | 6.12% | - |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Net margin21.4%vs -22.58%+195%
- ROIC (TTM)36.09%vs -2.38%+107%
- Debt / Equity-vs -+96%
- Market cap$22.29Bvs $5.71B+74%
PTCT leads on
- P/E (TTM)-vs 25.3x+182%
- Revenue CAGR 5y33.89%vs 2.01%+94%
- EV/EBIT6.2xvs 21.6x+71%
- Gross margin77.84%vs 57.79%+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.